All In Biotech

Drug Trial Radar · NCT06865079

53-Week Study Evaluating the Safety and Efficacy of Intra-articular Injections of TPX-100 With Mild to Severe Tibio-Femoral Osteoarthritis of the Knee

A Randomized, Double-blind, Placebo-controlled, 53-Week Study Evaluating the Safety and Efficacy of Intra-articular Injections of TPX-100 in Subjects With Mild to Severe Tibio- Femoral Osteoarthritis of the Knee

Last checked: Nov 19, 2026Latest source record: Feb 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 270 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

270

Planned (sponsor's estimate)

Start

May 9, 2025

Primary completion

Mar 25, 2027

Study completion Apr 15, 2027

Sponsor

Lead sponsor
OrthoTrophix, IncIndustry
Sponsor type
Industry
First posted
Mar 7, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

53-Week Study Evaluating the Safety and Efficacy of Intra-articular (IA) Injections of TPX-100 vs Placebo in Subjects with Mild to Severe Tibio-Femoral Osteoarthritis of the Knee

Conditions

  • Osteoarthritis (OA) of the Knee

Interventions

  • TPX-100 200mg, Once weekly for 4 weeksDrug

    TPX-100 (200 mg per dose) will be administered once-weekly (Week 1, 2, 3 \& 4) to a single target knee of the subject for 4 injections. TPX-100 can be administered by conventional methods such as subcutaneous or intra-articular injection.

  • PBSOther

    PBS / placebo for intra-articular injection administered once-weekly (Week 1, 2, 3 and 4) to a single target knee of the subject for 4 injections

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Toxicity Reaction (CTC 5.0 standard)Time frame: Baseline to Study Week 27 and Study Week 53

Locations

33 sites in 1 country. Site status is shown where the registry gives one.

  • Elite Clinical Network

    Scottsdale, Arizona

  • Noble Clinical Research

    Tucson, Arizona

  • Legent Orthopedic Hospital

    Carrolton, California

  • Medvin Clinical Research

    Covina, California

  • CORE Orthopaedic Medical Center

    Encinitas, California

  • Marvel Clinical Research (Elite Clinical Network)

    Huntington Beach, California

  • Medvin Clinical Research Center

    Riverside, California

  • Medvin Clinical Research Center

    Tujunga, California

  • Medvin Clinical Research Center

    Whittier, California

  • K2 Medical Research

    Maitland, Florida

  • Wellness Research Center

    Miami, Florida

  • Well Pharma Medical Research

    Miami, Florida

  • Las Mercedes Medical Research

    Miami, Florida

  • Drug Studies of America

    Marietta, Georgia

  • AMR Kansas City

    Kansas City, Kansas

  • University of Kansas Medical Center

    Kansas City, Kansas

  • AMR Lexington

    Lexington, Kentucky

  • Accurate Clinical Research Inc.

    Lake Charles, Louisiana

  • Mayo Clinic (Rochester)

    Rochester, Minnesota

  • Las Vegas Clinical Trials

    North Las Vegas, Nevada

  • Albuquerque Clinical Trials

    Albuquerque, New Mexico

  • Center for Clinical Research

    Winston-Salem, North Carolina

  • Hightower Clinical

    Oklahoma City, Oklahoma

  • University Orthopedics Center

    Altoona, Pennsylvania

  • University Orthopedics Center

    State College, Pennsylvania

  • AMR Knoxville

    Knoxville, Tennessee

  • Accurate Clinical Research, LLC

    Baytown, Texas

  • Texas Orthopedic Specialist

    Bedford, Texas

  • First Surgical Hospital

    Bellaire, Texas

  • Accurate Clinical Research

    Houston, Texas

  • Endeavor Clinical Trials

    San Antonio, Texas

  • CenExel

    Salt Lake City, Utah

  • Wasatch Clinical Research

    Salt Lake City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.